4-{5-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-1H-tetrazol-1-yl}benzoic acid, 250mg

H-D-Pro.OMe.HCl, 98%, 5g

5-Bromo-4-chloro-2-nitrobenzaldehyde, 97%, 10g

N-[5-(Methoxycarbonyloxy)-2,4-di(tert-butyl)phenyl]-4-oxo-1H-quinoline-3-carboxamide, 98%, 250mg

1-{[2-(trifluoromethyl)phenyl]methyl}-1,4-diazepane, 95.0%, 1g

1-N-Cbz-4-hydroxy-beta-proline, 97.0%, 5g

1-(BENZENESULFONYL)-6-IODO-2-METHYL-1H-INDOLE, 95.0%, 5g

1-Ethyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiourea, 97%, 1g

3-Bromo-6-chloro-2-fluoroaniline, 97%, 1g

6-Bromobenzo[d]oxazole-2-carboxylic acid, 98%, 250mg

Alkylbenzyl dimethyl ammonium chloride, 80% in water, 100 g, glass packaging

1,4-Dicyano-2-(trifluoromethoxy)benzene, 97.0%, 5g

GC capillary column ROTI®Cap-1 MS, 30 m, 0.32 mm, 0.25 µm, 1 Piece(s)